Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$191M |
| 2 |
Nike
NKE
|
+$190M |
| 3 |
UnitedHealth
UNH
|
+$158M |
| 4 |
Shopify
SHOP
|
+$153M |
| 5 |
TSMC
TSM
|
+$151M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palantir
PLTR
|
+$910M |
| 2 |
Microsoft
MSFT
|
+$668M |
| 3 |
Meta Platforms (Facebook)
META
|
+$351M |
| 4 |
Micron Technology
MU
|
+$244M |
| 5 |
Apple
AAPL
|
+$191M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.86% |
| 2 | Healthcare | 15.8% |
| 3 | Consumer Discretionary | 14.09% |
| 4 | Industrials | 8.98% |
| 5 | Financials | 8.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Veeva Systems
VEEV
$33.1B
| $42.3M | 0.06% |
201,200
+122,000
| +154% | +$26.8M |
|
377
Shell
SHEL
$254B
| $42.2M | 0.06% |
673,786
-12,200
| -2% | -$800K |
|
|
VMEO
378
DELISTED
Vimeo
VMEO
| $42.2M | 0.06% |
6,590,500
+419,700
| +7% | +$2.53M |
|
379
Moderna
MRNA
$21.8B
| $42M | 0.06% |
1,010,758
+700,458
| +226% | +$33.5M |
|
380
Hess Midstream
HESM
$5.24B
| $42M | 0.06% |
1,134,495
+30,200
| +3% | +$1.09M |
|
381
Travere Therapeutics
TVTX
$5.2B
| $42M | 0.06% |
2,409,514
+534,500
| +29% | +$9.45M |
|
382
Eli Lilly
LLY
$1.02T
| $41.8M | 0.06% |
54,120
-203,693
| -79% | -$169M |
|
383
Insulet
PODD
$11.5B
| $41.5M | 0.06% |
158,993
+49,900
| +46% | +$12.6M |
|
|
CWAN
384
DELISTED
Clearwater Analytics
CWAN
| $41.5M | 0.06% |
1,507,900
+1,202,900
| +394% | +$34.1M |
|
385
US Foods
USFD
$22.2B
| $41.3M | 0.06% |
612,000
+432,200
| +240% | +$28.4M |
|
386
National Healthcare
NHC
$3.53B
| $41.1M | 0.06% |
381,867
-9,400
| -2% | -$1.14M |
|
387
Wabtec
WAB
$49.1B
| $40.8M | 0.06% |
215,395
-173,000
| -45% | -$33.5M |
|
388
Takeda Pharmaceutical
TAK
$54.6B
| $40.8M | 0.06% |
3,079,400
-139,400
| -4% | -$1.91M |
|
389
Raymond James Financial
RJF
$33.8B
| $40.7M | 0.06% |
262,037
+69,000
| +36% | +$10.4M |
|
390
Chord Energy
CHRD
$7.9B
| $40.6M | 0.06% |
347,216
+138,600
| +66% | +$17.4M |
|
391
International Flavors & Fragrances
IFF
$20.2B
| $40.5M | 0.06% |
478,601
-28,099
| -6% | -$2.64M |
|
392
Westlake Corp
WLK
$9.03B
| $40.2M | 0.06% |
350,700
+182,600
| +109% | +$23.8M |
|
393
Genmab
GMAB
$17.7B
| $40.2M | 0.06% |
1,926,150
+139,722
| +8% | +$3.07M |
|
394
Louisiana-Pacific
LPX
$5.06B
| $40.2M | 0.06% |
388,200
-46,686
| -11% | -$5.08M |
|
395
Descartes Systems
DSGX
$6.44B
| $40.2M | 0.06% |
353,800
-15,900
| -4% | -$1.77M |
|
396
Ironwood Pharmaceuticals
IRWD
$696M
| $40.2M | 0.06% |
9,066,241
+469,043
| +5% | +$1.9M |
|
397
Brookfield Renewable
BEPC
$6.08B
| $40.1M | 0.06% |
1,449,495
-76,700
| -5% | -$2.36M |
|
398
Under Armour
UAA
$2.84B
| $40.1M | 0.06% |
4,837,800
+581,800
| +14% | +$5.32M |
|
399
Skywest
SKYW
$4.24B
| $40M | 0.06% |
399,324
+128,524
| +47% | +$13.1M |
|
400
JD.com
JD
$44.6B
| $39.7M | 0.06% |
1,143,700
+1,063,800
| +1,331% | +$41.2M |
|
Similar funds
Renaissance Technologies's Q4 2024 Portfolio in Review
As of Q4 2024, Renaissance Technologies held 4,032 positions worth $67.6B, up 1.6% from $66.5B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Renaissance Technologies's Q4 2024 filing shows 548 new, 1,485 increased, 1,480 reduced and 497 closed positions. Its largest new stake was UnitedHealth: 278,658 shares worth $141M. The largest sale was Palantir, an estimated $910M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2024 buy was UnitedHealth: 278,658 shares worth $141M.
- Renaissance Technologies added most to Alibaba in Q4 2024, an estimated $191M increase.
- Renaissance Technologies's biggest Q4 2024 reduction was Palantir, cutting an estimated $910M.
- Renaissance Technologies fully exited Arm in Q4 2024, selling an estimated $153M.
- Renaissance Technologies's ten largest holdings make up 10% of its $67.6B portfolio in Q4 2024.
- Renaissance Technologies opened 548 new positions and closed 497 in Q4 2024.
- Renaissance Technologies's portfolio value rose 1.6% quarter-over-quarter to $67.6B.
Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.